Back to School: How biopharma can reboot drug development. Access exclusive analysis here

AstraZeneca reports 2Q EPS

AstraZeneca (AZN; LSE:AZN) posted second quarter EPS of $0.45, a 15% increase over the $0.39 posted in

Read the full 177 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE